Modulating growth factor signaling through precise and novel treatments
Our goal is to preserve and restore organ function in a range of acute and chronic conditions associated with tissue injury, inflammation, fibrosis and degeneration.
About Us
Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas
News & Events
PR
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
January 2022
PR
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
December 2021
“We are determined to improve the lives of patients through innovation. With a broad European footprint, we have built a leading company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”
-
Tim Knotnerus, Chief Executive Officer
